Alzheimer's disease as type 3 diabetes: common pathophysiological mechanisms between Alzheimer's disease and type 2 diabetes
Open accessThe DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Globally, the incidence of type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) epidemics is increasing rapidly and has huge financial and emotional costs. The purpose of the current review article is to discuss the shared pathophysiological connections between AD and T2DM. Research findings are presented to underline the vital role that insulin plays in the brain’s neurotransmitters, homeostasis of energy, as well as memory capacity. The findings of this review indicate the existence of a mechanistic interplay between AD pathogenesis with T2DM and, especially, disrupted insulin signaling. AD and T2DM are interlinked with insulin resistance, neuroinflammation, oxidative stress, advanced glycosylation end products (AGEs), mitochondrial dysfunction and metabolic syndrome. Beta-amyloid, tau protein and amylin can accumulate in T2DM and AD brains. Given that the T2DM patients are not routinely evaluated in terms of their cognitive status, they are rarely treated for cognitive impairment. Similarly, AD patients are not routinely evaluated for high levels of insulin or for T2DM. Studies suggesting AD as a metabolic disease caused by insulin resistance in the brain also offer strong support for the hypothesis that AD is a type 3 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free radicals and antioxidants in normal physiological functions and human disease
Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T. D., Mazur, M., & Telser, J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.07.001 · Cited by 14,269 · cited 2×
“It leads to oxidation of proteins, lipids and DNA, causing damage to the mitochondria, as well as induction of genetic mutations in DNA/RNA [91]).”
BackgroundSaeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 1×
“It is estimated that the global diabetes mellitus (DM) prevalence will rise from 9.3% (463 million people) in 2019 to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045 [8].”
BackgroundInfluentialHearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“The strongest genetic risk factor for AD is the e4 allele of apolipoprotein E (APOE4) relative to the e3 allele and the protective e2 allele [5,6].”
BackgroundType 2 diabetes: principles of pathogenesis and therapy
Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61032-x · Cited by 2,662 · cited 2×
“This dysfunction means that the secretion of insulin by the β-cells of the pancreatic islets (β-cell dysfunction) as well as the action of insulin on insulin-sensitive tissues such as the liver, adipose tissue and muscle do not function normally for the body (insulin resistance) [9].”
BackgroundProtein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629 · cited 1×
“AD and T2DM are both diseases that involve the formation of amyloid in various parts of the body [42,43].”
BackgroundAdvanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261 · cited 1×
“These products are protein molecules or peptides that are formed as a result of the Maillard reaction, meaning they become glycated as a result of their exposure to sugars [105].”
BackgroundTau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251 · cited 1×
“In its normal state, tau protein is responsible for microtubule stability and regulating intracellular signaling [63–66].”
Background2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
Diabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175 · cited 1×
“Insulin resistance affects the way insulin works in target tissues and cells, leading to the well-known phenomenon of hyperglycemia, a condition in which too much glucose circulates in the blood plasma and characterizes T2DM [9] T2DM has also been associated with an increased risk of dementia [10,11] and of AD by 45–9…”
Background
Cited by
Items 101–200 of 346
Hypoglycemia and Alzheimer Disease Risk: The Possible Role of Dasiglucagon
Ali, N. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Hadi, N. R., Assiri, A. A., Alrouji, M., Welson, N. N., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2024) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-024-01489-y · Cited by 14
Yang, C., Zhang, H., Ma, Z., Fan, Y., Xu, Y., Tan, J., Tian, J., Cao, J., Zhang, W., Huang, G., et al. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.70029 · Cited by 11
Mani, V., & Arfeen, M. (2024) · Brain Sciences · doi:10.3390/brainsci14121191 · Cited by 12
Roney, M., Uddin, M. N., Khan, A. A., Fatima, S., Aluwi, M. F. F. M., Hamim, S. M. I., & Ahmad, A. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108378 · Cited by 13
Venuti, M. T., Roda, E., Brandalise, F., Sarkar, M., Cappelletti, M., Speciani, A. F., Soffientini, I., Priori, E. C., Giammello, F., Ratto, D., et al. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1455434 · Cited by 14
de Muniain, L. S., Escalada, P., Ramírez, M. J., & Solas, M. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70252 · Cited by 16
Siddiqui, A. J., Badraoui, R., Alshahrani, M. M., Snoussi, M., Jahan, S., Siddiqui, M. A., Khan, A., Sulieman, A. M. E., & Adnan, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306579 · Cited by 10
Green, C., Zaman, V., Blumenstock, K., Banik, N. L., & Haque, A. (2025) · Biomedicines · doi:10.3390/biomedicines13010132 · Cited by 13
“…as studies have discovered that an increase in insulin concentration in the brain affects the neurotransmitters responsible for regulating long-term memory enhancement and long-term memory suppression, which is a common deficiency seen in AD resulting in impaired memory and cognition [97,98].”
Brendborg, N., & Febbraio, M. A. (2025) · The Journal of Physiology · doi:10.1113/jp286747 · Cited by 12
“This is one of the pillars of the ‘Alzheimer’s as type 3 diabetes’ hypothesis, which has been reviewed in detail elsewhere (Michailidis et al., 2022).”
Xie, G., Jiang, G., Huang, L., Sun, S., Wan, Y., Li, F., Wu, B., Zhang, Y., Li, X., Xiong, B., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18060790 · Cited by 13
“This overlap has led some researchers to propose the concept of “type 3 diabetes” (brain-specific diabetes) [213–216].”
Liu, Y., Ma, X., Xu, J., Wang, X., Liu, L., Ren, X., Zhang, C., Zhou, S., Wang, Y., Guo, X., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.06.044 · Cited by 12
“Notably, these pathological findings align with clinical observations: cerebrospinal fluid (CSF) levels of AD-associated phosphorylated tau markers are elevated in diabetic patients, and brain tau deposition correlates positively with hemoglobin A1c (HbA1c) levels [41].”
Zong, R., Zhang, X., Dong, X., Liu, G., Zhang, J., Gao, Y., Zhang, Z., Ma, Y., Gao, H., & Gamper, N. L. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1375925 · Cited by 10
Malate dehydrogenase as a multi-purpose target for drug discovery
Fermaintt, C. S., & Wacker, S. (2024) · Essays in Biochemistry · doi:10.1042/ebc20230081 · Cited by 11
Majid, H., Islam, S. U., Kohli, S., & Nidhi, N. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01824-9 · Cited by 10
Exploring the cognitive impacts of diabetic neuropathy: a comprehensive review
Mian, M., Salehi, F., Patel, R., Tahiri, J., Bel-Hadj-Kacem, A., Alhaque, A., Eldin, R., & Reddy, P. H. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167892 · Cited by 13
Giofrè, F., Zaffina, I., Pelle, M. C., & Arturi, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1696419 · Cited by 11
Tsentidou, G., Μoraitou, D., Tsolaki, M., Masoura, E. V., & Papaliagkas, V. T. (2022) · Diagnostics · doi:10.3390/diagnostics12123017 · Cited by 10
“Moreover, the same findings have been supported by Michailidis et al. 2022 [87], who reviewed and discussed common pathophysiological mechanisms between Alzheimer Disease and type 2 diabetes mellitus; this review study suggests the frequent assessment of the cognitive status of patients with type 2…”
BackgroundSelf-citationCognitive impairment in type 2 diabetes mellitus: prospects for the use of metformin
Pashkovska, N. V. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.3.2023.1274 · Cited by 10
The role of antidiabetic drugs in the treatment of Alzheimer’s disease: systematic review
Ishmuratova, A. N., Abramov, M. A., Олегович, К. К., Ivanyuta, M. V., Shakirova, Z. F., Kitapova, A. I., Usmonov, M., Chernousova, L. M., Valeeva, L. I., Kuznetsova, A. Y., et al. (2023) · Problems of Endocrinology · doi:10.14341/probl13183 · Cited by 10
“Недавние исследования показывают, что БА имеет множество общих связей с состояниями, ассоцииро-ванными с инсулинорезистентностью, включая ней-ровоспаление, нарушение сигнализации инсулина, окислительный стресс, митохондриальную дисфунк-цию и метаболический синдром [10].”
Brain energetics and glucose transport in metabolic diseases: role in neurodegeneration
Méndez-Flores, O. G., Hernández‐Kelly, L. C., Olivares-Bañuelos, T. N., López‐Ramírez, G., & Ortega, A. (2024) · Nutritional Neuroscience · doi:10.1080/1028415x.2024.2306427 · Cited by 9
“This syndrome is associated with type 2 diabetes (T2D) and some psychiatric and neurodegenerative diseases (including Alzheimer ’ s diseases (AD)) [32 – 34].”
Hao, R., Hu, Y.-C., Wei, Y.-Y., Qin, X., & Lu, Y.-W. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106040 · Cited by 9
Anoush, M., Taghaddosi, N., Hosseini, Z. B., Rahmati, F., Bijani, S., Kalantari‐Hesari, A., & Hosseini, M. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.01.008 · Cited by 12
Traumatic Brain Injury and Alzheimer’s Disease: A Shared Neurovascular Hypothesis
Cognacq, G., Attwood, J. E., & DeLuca, G. C. (2025) · Neuroscience Insights · doi:10.1177/26331055251323292 · Cited by 11
Tian, Y., Jing, G., Yin, R., Ma, M., Cao, W., & Zhang, M. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149365 · Cited by 11
Siddiqui, F., Mishra, P., Khanam, S., Ranjan, S., Alam, P., Albalawi, T., Khan, S., & Mir, S. S. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70142 · Cited by 8
Lombardo, C., Musso, N., Bonacci, P. G., Lupo, G., Anfuso, C. D., Fatta, E. D., Ferri, R., Majzúnová, M., Scuto, M. C., & Salinaro, A. T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010169 · Cited by 9
“Recently, there has been a growing interest in the scientific community regarding the potential connection between AD and type 2 diabetes mellitus (T2DM), leading to the proposal of the conceptual term “type 3 diabetes mellitus” (T3DM) [8,9].”
High Risk of Metabolic Complications Due to High Consumption of Processed Foods
Vellapandian, C., & Singh, A. (2022) · Current Nutrition & Food Science · doi:10.2174/1573401318666220622162038 · Cited by 10
Bioinformatic prediction of the molecular links between Alzheimer’s disease and diabetes mellitus
Castillo-Velázquez, R., Martínez-Morales, F., Castañeda‐Delgado, J. E., García-Hernández, M. H., Herrera-Mayorga, V., Sánchez, F. A. P., Rivera, G., Rivas-Santiago, B. T., & Lara-Ramirez, E. E. (2023) · PeerJ · doi:10.7717/peerj.14738 · Cited by 10
“DISCUSSION AD and DM2 are complex diseases for which a link have been suggested (Michailidis et al., 2022).”
BackgroundSexual and Metabolic Differences in Hippocampal Evolution: Alzheimer’s Disease Implications
Martínez-Martos, J. M., Cantón-Habas, V., Rich‐Ruiz, M., Reyes-Medina, M. J., Ramírez-Expósito, M. J., & Carrera-González, M. P. (2024) · Life · doi:10.3390/life14121547 · Cited by 9
Role and mechanism of molecular hydrogen in the treatment of Parkinson’s diseases
Wang, F., Zhang, G., & Zhai, Q. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1576773 · Cited by 11
Bramen, J. E., Siddarth, P., Popa, E. S., Kress, G. T., Rapozo, M. K., Hodes, J. F., Ganapathi, A. S., Slyapich, C. B., Glatt, R. M., Pierce, K. P., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230458 · Cited by 8
Xu, G., An, Y., Du, Y., Cao, Z., Zheng, J., Wang, J., Li, T., Lei, X. G., & Lu, Y. (2025) · iMetaOmics. · doi:10.1002/imo2.70020 · Cited by 7
Li, Z., Zhang, Y., Su, R. J., Yang, J., Chen, F., Chen, L., Yao, C., Li, S., Cui, P., Meng, X., et al. (2025) · Phytotherapy Research · doi:10.1002/ptr.70006 · Cited by 8
“Recent studies have underscored the significance of brain insulin resistance and cerebral glucose metabolism in individuals with diabetic AD (Hamzé et al. 2022; Michailidis et al. 2022; Minhas et al. 2024).”
Alzheimer’s disease: a jigsaw puzzle comprised of different types of programmed cell death pieces
Wang, Y., Mu, D., Li, Y., Liu, C., Feng, J., Lai, Y., & Lou, G. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149861 · Cited by 9
Yuan, J., Dong, X., Gao, Y. L., & Nao, J. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00744 · Cited by 8
“For instance, oxidative stress and neuroinflammation, key drivers of AD, are exacerbated by T2DM-related insulin resistance (IR) and chronic hyperglycemia, which promote neuronal damage [14,15].”
Boukhalfa, W., Jmel, H., Kheriji, N., Gouiza, I., Dallali, H., Hechmi, M., & Kéfi, R. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1114810 · Cited by 8
Gong, Y., Luo, H., Li, Z., Feng, Y., Liu, Z., & Chang, J. (2023) · Metabolites · doi:10.3390/metabo13080954 · Cited by 7
“Moreover, BBB injury, inflammation, oxidative stress, mitochondrial dysfunction, glucose metabolism dysfunction, AGEs, and vascular dysfunction also play a role in the interplay between DM and AD [35].”
BackgroundGendron, W. A. C., Fertan, E., Roddick, K. M., Wong, A. A., Maliougina, M., Hiani, Y. E., Anini, Y., & Brown, R. E. (2024) · Physiology & Behavior · doi:10.1016/j.physbeh.2024.114583 · Cited by 7
Relationships Between APOE, Type 2 Diabetes, and Cardiovascular Disease in Postmenopausal Women
Dunk, M. M., Driscoll, I. F., Espeland, M. A., Hayden, K. M., Liu, S., Nassir, R., Natale, G., Shadyab, A. H., & Manson, J. E. (2024) · The Journals of Gerontology Series A · doi:10.1093/gerona/glae246 · Cited by 8
“APOE has been implicated as a susceptibility locus for both T2DM and CVD, which could provide a potential link between cardiometabolic dysfunction and AD risk.”
InfluentialAlves, S. S., Rossi, L., de Oliveira, J. A. C., Servilha‐Menezes, G., Grigório-de-Sant’Ana, M., Mazzei, R. F., Almeida, S. S., Sebollela, A. S., da Silva-Júnior, R. M. P., & Garcia‐Cairasco, N. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04844-2 · Cited by 7
Kurtukova, V., Aktas, S., Pupure, J., Narbute, K., Muceniece, R., & Piļipenko, V. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05079-x · Cited by 6
Bowirrat, A., Pinhasov, A., Bowirrat, A., & Badgaiyan, R. D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178253 · Cited by 8
“Therefore, the deficiency of IDE favors extracellular deposits of amyloid-β neurotic plaques, which is one of the underlying neuropathological hallmarks of AD [181,184].”
The interplay between metabolic health factors and stroke incidence in aging populations
Zhang, C., Xiong, T., Ren, K., Wu, H., Cai, S., & Wang, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1646643 · Cited by 7
“This neuroin fl ammatory response is harmful to neuronal integrity and function, contributing to cognitive de fi cits observed in diabetic patients (33, 34).”
Zhang, Y., Long, X., Yao, B.-F., Tian, J., Peng, J., & Luo, X. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.09.026 · Cited by 7
Amorim, M. D. S. D. N., Rates, E. R. D., Vitoria, D. A. C. M. I., Filho, J. F. S. D., dos Santos, C. C., Santos‐Oliveira, R., Gaspar, R. S., Sanches, J. R., Pinto, B., Paes, A. M. D. A., et al. (2024) · ACS Omega · doi:10.1021/acsomega.4c05869 · Cited by 6
Reducing Alzheimer’s disease risk with SGLT2 inhibitors: From glycemic control to neuroprotection
Alami, M., Morvaridzadeh, M., Khayari, A. E., Boumezough, K., Fatimy, R. E., Khalil, A., Fülöp, T., & Berrougui, H. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102751 · Cited by 6
Song, Z., Yu, W., Jin, Y., Zhou, M.-F., He, C., Li, Z., He, J., Chen, Q., Li, P., Yi, Y., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120352 · Cited by 7
Badran, A., & Gbreel, M. I. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08411-4 · Cited by 7
Li, C., Qian, H., Feng, L., & Li, M. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-240053 · Cited by 6
Accelerated Aging and the Life Course of Individuals Born Preterm
Bousquet, A., Sanderson, K., O’Shea, T. M., & Fry, R. C. (2023) · Children · doi:10.3390/children10101683 · Cited by 10
“Higher insulin levels, reflecting lower sensitivity, are associated with greater age-related cognitive decline [49], and Alzheimer’s disease and type 2 diabetes mellitus share numerous mechanistic pathways [50].”
BackgroundGuo, X., Wang, F., Zheng, M., Li, L., Li, L., Wang, J., Miao, S., Ma, S., & Shi, X. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2289038 · Cited by 6
“…cytokines (IL-6, TNF-a ) may result in alterations in the synthesis of various neurotransmitters (Gaspar et al., 2016) and increase blood-brain barrier permeability and vascular susceptibility, leading to neuronal damage and cognitive dysfunction (Michailidis et al., 2022, Zhao et al., 2019).”
Li, R., Lü, B., Li, Q., Hu, J., Huang, Y., Wang, Y., Qin, G., Zhang, W., Su, Q., Zhu, J., et al. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.11.001 · Cited by 6
Exploring DPP IV inhibitors for Alzheimer’s disease: Bridging diabetes and neurodegeneration
Pattanaik, S., Prusty, S. K., & Sahu, P. K. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149342 · Cited by 6
Mohammed, O., & Kelemu, T. (2025) · Health Science Reports · doi:10.1002/hsr2.71065 · Cited by 6
“These strong ties between AD and diabetes explain why AD is commonly referred to as type 3 diabetes [22].”
Manzoor, M., Iqbal, M. O., Wang, D., Barkat, M. Q., Khan, M. S., Syed, W., Al‐Rawi, M. B. A., & Ni, F. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120374 · Cited by 6
Shafiee, A., Akhlaghi, A., Ellstrom, A., Mohammadi, S. O., Shafiee, A., & Sathyamoorthy, M. (2025) · International Journal of General Medicine · doi:10.2147/ijgm.s539967 · Cited by 6
Majid, H., Islam, S. U., Kohli, S., & Nidhi (2025) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-025-00703-0 · Cited by 5
Lee, H., & Lim, Y. (2025) · Nutrients · doi:10.3390/nu17223615 · Cited by 6
“…suggests that structured exercise and targeted nutritional strategies can enhance the secretion of muscle-derived factors known as myokines, which play key roles in neurogenesis, synaptic plasticity, and inflammation, thereby supporting the functional relevance of the muscle–brain axis [6–8].”
Wang, B., Shao, Y., & Liang, R. (2026) · Journal of Integrative Neuroscience · doi:10.31083/jin44389 · Cited by 5
Mechanistic Links Between the Gut Microbiome and Longevity Therapeutics
Garzon-Escamilla, N., Medina-Cardena, M., Roy, P., Trent, J., Jamous, J., Somesan, Y., & Denslow, S. (2026) · Biomedicines · doi:10.3390/biomedicines14020316 · Cited by 7
“Recent evidence indicates shared mechanistic pathways between neurodegenerative diseases and T2D [169], highlighting the potential of GLP-1R agonists as therapeutic agents to ameliorate neurodegeneration.”
Jorda, A., Alvarez-Gamez, K., Vergani, S., Paba, I., Pérez, M., Aldasoro, M., Vila, J. M., & Vallés, S. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125565 · Cited by 180
“Alterations in brain insulin signalling have been associated with ageing and several neurodegenerative disorders, including Alzheimer’s disease (AD) [5–10].”
Deru, L. S., Gipson, E. Z., Hales, K. E., Bikman, B. T., Davidson, L. E., Horne, B. D., LeCheminant, J. D., Tucker, L. A., & Bailey, B. W. (2024) · Nutrients · doi:10.3390/nu16010164 · Cited by 5
“…traditionally been deemed a genetic disease but is now popularly expressed as type 3 diabetes because of shared pathophysiological mechanisms with type 2 diabetes, namely neuroinflammation, oxidative stress, advanced glycosylation end products, mitochondrial dysfunction, and insulin resistance [8].”
BackgroundDiabetes mellitus and Alzheimer's disease: Vacuolar adenosine triphosphatase as a potential link
Guo, B., Li, Q., Liu, X. M., Luo, G., Wu, Y., & Nie, J. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16286 · Cited by 5
“AD and T2DM share many common patho-physiological features and signalling pathways, such as autophagy, IR, glycolysis, oxidative stress, AGE, mitochondrial dysfunction and metabolic syndrome, but the key links remain unclear (Michailidis et al., 2022).”
BackgroundLiu, S., Chen, H., He, X., & Yang, X. (2024) · Neurology Research International · doi:10.1155/2024/5200222 · Cited by 7
“Furthermore, the potential link between AD and brain insulin resistance [45] has made insulin sensitizers like metformin a focus in AD treatment.”
BackgroundNguyen, D. P. Q., Jallow, A. W., Lin, Y., & Lin, Y.-F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126640 · Cited by 5
“Previous studies have demonstrated a significant link between AD and T2DM, suggesting that they may involve some common molecular and cellular pathways [19–21].”
BackgroundThe role and mechanism of dapagliflozin in Alzheimer disease: A review
Chen, P., Liang, L., Dai, Y., & Hui, S. (2024) · Medicine · doi:10.1097/md.0000000000039687 · Cited by 7
Shen, Y., Li, H., Yang, Q., Zhang, K., Liu, S., Zhang, N., Li, C., Yu, S., Xie, L.-S., & Wu, Q. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05147-2 · Cited by 6
Can Alzheimer's Disease Be Secondary to Type-2 Diabetes Mellitus?
Jangra, V., & Tople, J. P. (2022) · Cureus · doi:10.7759/cureus.31273 · Cited by 8
“Some experts have referred to AD as type 3 DM due to the higher incidence of late-onset AD in DM [4].”
BackgroundLiu, X., Che, K., Li, Q., Wu, X., Zeng, D., Du, X., & Qing, S. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01342-y · Cited by 4
“As a complication of T2DM, diabetic cognitive impairment is easily transformed into AD with the development of the disease course(Michailidis et al. 2022).”
Santerre, J. L., Colon, M., Pike, B. L., & Kiessling, C. Y. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149978 · Cited by 4
Zhang, J., Zheng, Z., Liu, Y., Feng, S. Q., & Feng, G. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c06216 · Cited by 5
Midan, H. M., Wasfey, E. F., Doghish, A. S., Kamal, M. M., & Kassem, D. H. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02739-w · Cited by 4
“In addition, insulin dysregulation contributes to oxidative stress, neuronal inflammation, and apoptosis, further exacerbating cognitive deficits [238].”
Repurposing dapagliflozin for Alzheimer's disease: a mechanistic exploration
Saeed, M. M. (2024) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-024-00751-w · Cited by 5
Liu, Y., Wang, X., Ren, X., Zhang, C., Zhou, S., Wang, Y., Xu, J., Liu, L., Wang, Y., & Yuan, L. (2024) · Journal of the American Nutrition Association · doi:10.1080/27697061.2024.2401592 · Cited by 5
Yang, Y., Guan, P.-P., & Wang, P. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117223 · Cited by 5
A novel two-tier feature selection model for Alzheimer’s disease prediction
Maju, S. V., & S, G. P. O. (2024) · Indonesian Journal of Electrical Engineering and Computer Science · doi:10.11591/ijeecs.v33.i1.pp227-235 · Cited by 4
Alves, S. S., Servilha‐Menezes, G., Rossi, L., de Oliveira, J. A. C., Grigório-de-Sant’Ana, M., Sebollela, A. S., da Silva-Júnior, R. M. P., & Garcia‐Cairasco, N. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02896-1 · Cited by 4
“…a state of brain insulin resistance (Steen et al. 2005; De La Monte and Wands 2008; Kandimalla et al. 2017; Rorbach-Dolata and Piwowar 2019; Nguyen et al. 2020; Michailidis et al. 2022), though there is no standard consensus on the specific parameters that define an insulin-resistant brain.”
Gipson, E. Z., Deru, L. S., Graves, P. G., Jacobsen, C. G., Peterson, N. E., & Bailey, B. W. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-00920-5 · Cited by 4
“Studies have even shown that Alzheimer’s disease follows a similar pathological development as type 2 diabetes, including mechanisms linked to insulin resistance, neuroinflammation and oxidative stress [11].”
Xie, R., Liu, Z., Zheng, J., Tan, Q., Wu, H., & Liang, Y. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01975-w · Cited by 3
Sayed, A. M. E., El‐Hawary, S. S., Elimam, H., Raey, M. A. E., Mouhamed, A. A., zokalih, A. H., Bassam, S. M., & Mohyeldin, M. M. (2025) · Fitoterapia · doi:10.1016/j.fitote.2025.106943 · Cited by 3
Bramen, J. E., Siddarth, P., Popa, E. S., Kress, G. T., Rapozo, M. K., Hodes, J. F., Ganapathi, A. S., Sparks, W. M., Tongson, Y. M., Torres, A. M., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251388933 · Cited by 3
“61 Both are strongly associated with cognitive decline 61 and lead to amyloid-β (A β ) and neuro fi brillary tangle formation.”
Xu, S., Wang, X., Yang, D., Zhang, D., Du, L.-N., Chen, Q., Yang, Y., Lin, L., Shen, J., & Wu, J.-L. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02151-4 · Cited by 3
Babu, K. S., Gupta, V., Kaur, H., Arunprasad, V. K., Kapil, L., Choudhary, N., & Kumar, D. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01684-z · Cited by 4
“…this is an off-the-cuff, non-diagnostic notion and its boundaries and cause-effect relationships are the subject of controversy, with a number of authors construing it as a mechanistic perspective for AD-like neurodegeneration rather than as an independent clinical entity (Michailidis et al. 2022).”
RAGE Axis in the Pathogenesis and Treatment of CNS Neurodegeneration in Long-Term Hyperglycemia
Wasilewska, B., Mazur, U., Kordas, B., Mizia, P., & Juranek, J. K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041881 · Cited by 7
Chen, R., Fan, S., Di, C., Wu, H., Shi, Z., Liu, F., Lv, Z., Liu, S., & Ji, Y. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1731547 · Cited by 5
“…insulin responsiveness in target tissues (Park et al., 2015), with common forms predominantly driven by energy intake-expenditure imbalance rather than genetic predisposition (Michailidis et al., 2022), predisposing individuals to obesity and type 2 diabetes (Sêdzikowska and Szablewski, 2021).”
Giuffrè, G. M., Scalese, A., QUARANTA, D., Donnarumma, F., Vita, M. G., Carrozza, C., Rossini, P. M., Calabresi, P., & Marra, C. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107352 · Cited by 3
Attia, M. S. M., Ahmad, S. F., Nadeem, A., Ansari, M. A., Al‐Hamamah, M. A., Harisa, G. I., Bakheet, S. A., Emran, T. B., Singh, T., & Attia, S. M. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01870-4 · Cited by 4
“Thus, AD can be regarded as a metabolic disorder resulting from resistance to insulin/ insulin-like growth factor-1 (IGF-1) in the brain, suggesting classifying it as type 3 diabetes mellitus (Michailidis et al. 2022 ).”
Wang, G. (2024) · International Journal of Clinical and Experimental Pathology · doi:10.62347/chbj5517 · Cited by 3
Berezutsky, М. А., Дурнова, Н. А., Kurchatova, M. N., & Matvienko, U. A. (2025) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20251250217 · Cited by 3
Tozihi, M., Nourazarian, A., Yousefi, H., & Dehghan, G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177526 · Cited by 3
Rodríguez‐Casado, A., Álvarez, M., Merino, J. J., Tolédano, A., & Tolédano, A. (2025) · Current Alzheimer Research · doi:10.2174/0115672050375461250325074826 · Cited by 5
Андреевна, Л. Е., Shevelyova, M. P., Андреевна, В. А., Deryusheva, E. I., Chaplygina, A. V., Rastrygina, V. A., Валериевич, М. А., Alikova, V. D., Nazipova, A. A., Permyakova, M. E., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094095 · Cited by 3
Kasanami, Y., Yamamoto, T., Miyamoto, T., Matzno, S., Sakakibara, M., Iwaki, M., & Kawabata, A. (2023) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b23-00385 · Cited by 4
Wu, Y., Zhong, J., Wang, J., Li, H., Chen, X., Xia, X., & Zhou, J. (2024) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2024.06.003 · Cited by 3
Knezović, A., Hosch, M., Hamann, C. S., Popp, S., Ortega, G., Barilar, J. O., Grünblatt, E., Monoranu, C., Riederer, P. F., Šalković‐Petrišić, M., et al. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02979-z · Cited by 5
“The important role of insulin in energy homeostasis, memory enhancement and its effect on brain neurotransmitters leads to the hypothesis of AD being a “Type 3 diabetes” (de la Monte & Wands 2005; Janoutová et al. 2022; Michailidis et al. 2022).”
Winslow, W., Judd, J. M., Tallino, S., Roust, L. R., Filippis, E. D., Brown, B., Katsanos, C. S., & Velazquez, R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.24.639990 · Cited by 3
“Furthermore, impaired insulin signaling contributes to cognitive decline by promoting Aβ plaque accumulation, tau hyperphosphorylation, and ultimately neurodegeneration—all hallmarks of AD [8,9].”
Singh, R., Jain, S., Paliwal, V., Verma, K., Paliwal, S., & Sharma, S. K. (2024) · Drug Development Research · doi:10.1002/ddr.70026 · Cited by 2
“GHM is a vital clinical finding of AD (Wang, Yan, et al. 2016; de la Monte, Tong, and Wands 2018; Michailidis et al. 2022; Koepsell 2020, Frisardi et al. 2010).”
Moreira‐Silva, D., Yuksel, M., Ponnusamy, M., Hansen, M. T., McMillan, J. D., Geethakrishnan, S., Wang, S., Collier, L. A., & Thinakaran, G. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101602 · Cited by 3
“3,6,7 The aggregation of toxic amylin oligomers in the pancreas is one of the pathological hallmarks of diabetes identified 110 years ago by Opie.”
Song, B., Yue, D., Yan, H., Feng, L., & Li, M. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s531909 · Cited by 3
“94,95 Consequently, neuroinflammation exacerbates further damage to the BBB, resulting in even greater permeability.”
Metadata
- Authors
- Michailidis, M., Moraitou, D., Tata, D. A., Kalinderi, K., Papamitsou, T., & Papaliagkas, V.
- Affiliations
- Laboratory of Psychology, School of Psychology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
- Aristotle University of Thessaloniki (GR)
- International Hellenic University (GR)
- Corresponding author
- Papaliagkas, Vasileios
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-02-28
- Volume
- 23
- Issue
- 5
- Pages
- 2687
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8910482
- OpenAlex
- W4214581316
- Cited by
- 330
- References
- 150
- Citations by year
- 2026: 79 · 2025: 110 · 2024: 71 · 2023: 61 · 2022: 9
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Keywords
- Alzheimer's disease, type 2 diabetes, type 3 diabetes, insulin resistance, insulin signaling, neuroinflammation, oxidative stress, advanced glycation end products, mitochondrial dysfunction, metabolic syndrome, amyloid-beta, tau protein, amylin, cognitive impairment, brain energy homeostasis
- MeSH terms
- Alzheimer Disease, Brain, Diabetes Mellitus, Type 2, Humans, Insulin, Insulin Resistance, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
